Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Multidrug-resistant tuberculosis.

Spigelman M, Compton C, Gheuens J; Critical Path to TB Drug Regimens.

N Engl J Med. 2012 Nov 29;367(22):2155; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA3. No abstract available.

PMID:
23190231
2.

Multidrug-resistant tuberculosis.

Chai SJ, Rao CY, Varma JK.

N Engl J Med. 2012 Nov 29;367(22):2154-5; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA2. No abstract available.

PMID:
23190230
3.

Confronting multidrug-resistant tuberculosis.

Chaisson RE, Nuermberger EL.

N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478. No abstract available.

PMID:
22670908
4.

Multidrug-resistant tuberculosis.

D'Ambrosio L, Centis R, Migliori GB.

N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA1. No abstract available.

5.

[Tuberculosis: new treatment options and updated recommendations].

Schaberg T.

Dtsch Med Wochenschr. 2013 Apr;138(14):725-7. doi: 10.1055/s-0032-1332867. Epub 2013 Mar 26. Review. German. No abstract available.

PMID:
23533039
6.

[New antitubercular agents are not where where we need them to be].

Nau JY.

Rev Med Suisse. 2015 Dec 16;11(499):2408-9. French. No abstract available.

PMID:
26852561
7.

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC.

N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196. Erratum in: N Engl J Med. 2015 Dec 17;373(25):e29. Stuckia, David [corrected to Stucki, David].

8.

Drug-resistance mechanisms and tuberculosis drugs.

Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME.

Lancet. 2015 Jan 24;385(9965):305-7. doi: 10.1016/S0140-6736(14)62450-8. No abstract available.

9.

Delamanid: first global approval.

Ryan NJ, Lo JH.

Drugs. 2014 Jun;74(9):1041-5. doi: 10.1007/s40265-014-0241-5. Review.

PMID:
24923253
10.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

11.

The worldwide epidemic of multidrug-resistant tuberculosis.

The Lancet Infectious Diseases.

Lancet Infect Dis. 2011 May;11(5):333. doi: 10.1016/S1473-3099(11)70105-0. No abstract available.

PMID:
21530885
12.

Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.

Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D.

Int J Infect Dis. 2015 Mar;32:56-60. doi: 10.1016/j.ijid.2014.12.012. Review.

13.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

14.

Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.

Zhang Q, Liu Y, Tang S, Sha W, Xiao H.

Cell Biochem Biophys. 2013;67(3):957-63. doi: 10.1007/s12013-013-9589-5.

PMID:
23546935
15.

New drug combination may shorten tuberculosis treatment, study says.

Mayor S.

BMJ. 2015 Mar 18;350:h1518. doi: 10.1136/bmj.h1518. No abstract available.

PMID:
25788408
16.

New effective antituberculosis regimens.

Sotgiu G, Migliori GB.

Lancet. 2015 May 2;385(9979):1703-4. doi: 10.1016/S0140-6736(14)62303-5. Epub 2015 Mar 18. No abstract available.

PMID:
25795077
17.

Delamanid for Extensively Drug-Resistant Tuberculosis.

Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H.

N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. No abstract available.

18.

OPC-67683.

[No authors listed]

Tuberculosis (Edinb). 2008 Mar;88(2):132-3. doi: 10.1016/S1472-9792(08)70017-9. Review. No abstract available.

PMID:
18486051
19.

Access sought to tuberculosis drug from nutraceutical company.

Gruber K.

Nat Med. 2015 Feb;21(2):103. doi: 10.1038/nm.3805. Epub 2015 Feb 2. No abstract available.

PMID:
25642939
20.

Novel drugs against tuberculosis: a clinician's perspective.

Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC.

Eur Respir J. 2015 Apr;45(4):1119-31. doi: 10.1183/09031936.00162314. Epub 2014 Nov 27. Review.

Items per page

Supplemental Content

Write to the Help Desk